Cipla Verna Facility USFDA Inspection Classified VAI

Cipla Ltd has announced that its manufacturing facility in Verna, Goa, India, has been classified as Voluntary Action Indicated (VAI) following a routine cGMP inspection and a Pre-Approval Inspection (PAI) by the USFDA. The inspection took place between April 6th to 17th, 2026, and the classification was communicated by the USFDA on June 10th, 2026. This classification suggests that while issues were noted, they do not currently warrant mandatory regulatory action from the USFDA.